Evidence map›Paper›PMID 38957926›Full record

ArticleBioanalysis2024

Solving selectivity issues in LBAs: case study using Gyrolab to quantify CB307, a bispecific Humabody in human serum.

Thomas Wilford, Phillip D Bartlett, Anna Schlag, Lukas Jasaitis, Hardev Pandha, Andrew J Pierce, Richard Hughes

Abstract readClinical Trial, Phase I
In one paragraph

Article in Bioanalysis, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Thomas WilfordResolian, Fordham, Cambridgeshire CB7 5WW, United Kingdom of Great Britain & Northern Ireland.
Phillip D BartlettCrescendo Biologics Limited, Cambridge CB22 3AT, United Kingdom of Great Britain & Northern Ireland.
Anna SchlagCrescendo Biologics Limited, Cambridge CB22 3AT, United Kingdom of Great Britain & Northern Ireland.
Lukas JasaitisCrescendo Biologics Limited, Cambridge CB22 3AT, United Kingdom of Great Britain & Northern Ireland.
Hardev PandhaUniversity of Surrey, School of Biosciences, Guildford GU2 7XH, Surrey, United Kingdom of Great Britain & Northern Ireland.
Andrew J PierceCrescendo Biologics Limited, Cambridge CB22 3AT, United Kingdom of Great Britain & Northern Ireland.
Richard HughesResolian, Fordham, Cambridgeshire CB7 5WW, United Kingdom of Great Britain & Northern Ireland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antibodies, BispecificHumansImmunoassayAntibodies, BispecificCB307disease stateGyrolabhumabodyimmunoassayLBAmatrix effectsMRDPKselectivity

Identifiers

PMID38957926
PMCPMC11389741

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.